WO2008121467A3 - Combination therapy for treating cancer - Google Patents

Combination therapy for treating cancer Download PDF

Info

Publication number
WO2008121467A3
WO2008121467A3 PCT/US2008/055223 US2008055223W WO2008121467A3 WO 2008121467 A3 WO2008121467 A3 WO 2008121467A3 US 2008055223 W US2008055223 W US 2008055223W WO 2008121467 A3 WO2008121467 A3 WO 2008121467A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination therapy
treating cancer
cell growth
provides
tyrosine kinase
Prior art date
Application number
PCT/US2008/055223
Other languages
French (fr)
Other versions
WO2008121467A2 (en
Inventor
Kwok-Kin Wong
Geoffrey Shapiro
Danan Li
Takeshi Shimamura
Original Assignee
Dana Farber Cancer Inst Inc
Kwok-Kin Wong
Geoffrey Shapiro
Danan Li
Takeshi Shimamura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Kwok-Kin Wong, Geoffrey Shapiro, Danan Li, Takeshi Shimamura filed Critical Dana Farber Cancer Inst Inc
Publication of WO2008121467A2 publication Critical patent/WO2008121467A2/en
Publication of WO2008121467A3 publication Critical patent/WO2008121467A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The invention provides a method of inhibiting cell growth, inducing apoptosis and treating cancer by combination therapy with a tyrosine kinase inhibitor and an mTOR inhibitor.
PCT/US2008/055223 2007-02-28 2008-02-28 Combination therapy for treating cancer WO2008121467A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89203907P 2007-02-28 2007-02-28
US60/892,039 2007-02-28

Publications (2)

Publication Number Publication Date
WO2008121467A2 WO2008121467A2 (en) 2008-10-09
WO2008121467A3 true WO2008121467A3 (en) 2008-12-18

Family

ID=39523658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055223 WO2008121467A2 (en) 2007-02-28 2008-02-28 Combination therapy for treating cancer

Country Status (1)

Country Link
WO (1) WO2008121467A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006021142D1 (en) 2005-02-03 2011-05-19 Gen Hospital Corp METHOD FOR THE TREATMENT OF GEFITINIB-RESISTANT CANCER
RU2451524C2 (en) 2005-11-04 2012-05-27 Вайет Anti-tumour combinations mtor inhibitors, herceptin and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
PT2310011E (en) 2008-06-17 2013-10-07 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
PT2326329T (en) 2008-08-04 2017-02-14 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
PT3000467T (en) 2009-04-06 2023-03-30 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
SI2608792T1 (en) 2010-08-26 2018-02-28 Boehringer Ingelheim International Gmbh Methods of administering an egfr inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020266A1 (en) * 2001-08-07 2003-03-13 Wyeth Antineoplastic combinations
WO2004004644A2 (en) * 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
WO2006084058A2 (en) * 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
WO2007056118A1 (en) * 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020266A1 (en) * 2001-08-07 2003-03-13 Wyeth Antineoplastic combinations
WO2004004644A2 (en) * 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
WO2006084058A2 (en) * 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
WO2007056118A1 (en) * 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DI COSIMO S., ET AL: "Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001)", JOURNAL OF CLINICAL ONCOLOGY, 2004 ASCO ANNUAL MEETING PROCEEDINGS, vol. 22, no. 14S, 2004, XP008097447 *
LI D ET AL: "Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy", CANCER CELL 20070710 US, vol. 12, no. 1, 10 July 2007 (2007-07-10), pages 81 - 93, XP002499660, ISSN: 1535-6108 *
MILTON D.T., ET AL: "Phase I/II Trial of Gefitinib and RAD001 (Everolimus) in Patients (pts) with Advanced Non-Small Lung Cancer (NSCLC)", JOURNAL OF CLINICAL ONCOLOGY, 2005 ASCO ANNUAL MEETING PROCEEDINGS, vol. 23, no. 16S,1, 2005, XP008097428 *
PLUMMER R ET AL: "Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumours with mutated EGFR", EJC SUPPLEMENTS, vol. 4, no. 12, November 2006 (2006-11-01), & 18TH SYMPOSIUM ON MOLECULAR TARGETS AND CANCER THERAPEUTICS; PRAGUE, CZECH REPUBLIC; NOVEMBER 07 -10, 2006, pages 173 - 174, XP002499659, ISSN: 1359-6349 *
SOEJIMA K ET AL: "Augmented growth inhibition of human NSCLC cells resistant to EGFR-tyrosine kinase inhibitor (TKI) by a combination of dual TKI of EGFR/VEGFR2 (AEE788) and mTOR inhibitor (RAD001)", EJC SUPPLEMENTS, vol. 4, no. 12, November 2006 (2006-11-01), & 18TH SYMPOSIUM ON MOLECULAR TARGETS AND CANCER THERAPEUTICS; PRAGUE, CZECH REPUBLIC; NOVEMBER 07 -10, 2006, pages 183, XP002499658, ISSN: 1359-6349 *

Also Published As

Publication number Publication date
WO2008121467A2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
PH12017500930A1 (en) Hsp90 inhibitor combinations
WO2007087245A3 (en) Ret tyrosine kinase inhibition
MX346379B (en) Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer.
WO2008021389A3 (en) Using pi3k and mek modulators in treatments of cancer
WO2007123892A3 (en) Raf inhibitors and their uses
MX2009008132A (en) Combination therapy with angiogenesis inhibitors.
WO2008033408A3 (en) Methods for identifying compounds that modulate cell signaling and methods employing such compounds
EA201300810A1 (en) ANTI-TRACT THERAPY USING DOUBLE INHIBITORS KINAZ AURORA / MEK
WO2008121467A3 (en) Combination therapy for treating cancer
WO2008080001A3 (en) Compounds and methods for kinase modulation, and indications therefor
IN2012DN03012A (en)
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2009108860A3 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2008007072A8 (en) Methods for cancer treatment using tak1 inhibitors
WO2010071846A3 (en) Compounds for treating neuropsychiatric conditions
IL197633A0 (en) Methods for treating cancer with mva
IL195152A0 (en) Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
MX2007005115A (en) Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases.
WO2009064938A9 (en) Method of treating arthritis
WO2010002845A3 (en) Quinazoline derivatives
WO2008112129A3 (en) Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors
WO2007143146A3 (en) Method of treating inflammatory diseases using tyroskine kinase inhibitors
WO2009158374A3 (en) Inhibitors of akt activity
WO2009152210A3 (en) Coumarin compounds and their use for treating cancer
EP2073843A4 (en) Methods of diagnosing, treating, or preventing plasma cell disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08730913

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009551838

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 08730913

Country of ref document: EP

Kind code of ref document: A2